Aphexda Generic: When Will Generic Motixafortide Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Aphexda Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? September 2030 About 4 years away Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
- When does the last patent end? December 2041 2 patents listed with the FDA Why is a generic expected sooner?
- Can you buy a generic today? Not yet No company lists one for sale
Generic motixafortide acetate is expected to be available in September 2030, about 4 years away. None is for sale yet.
Why September 2030?
It is when Aphexda’s FDA protection for orphan drug ends. Seven years of protection for a use in a rare disease. We rate it probable: more likely than not, but it can still move.
If Aphexda’s last patent runs to December 2041, how can a generic come sooner?
The 2 patents that run past the expected month, to December 2041 (12,257,285 and 12,268,725), cover the product’s formulation. A patent like that protects one way of making or using the medicine, not the medicine itself. A generic company can often make its version a different way or leave that use off its label, or a court can rule the patent invalid or not infringed. That is why the expected month comes before the last protection ends. See the road to a generic
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).
Will the generic cost less?
Usually, but no company is recorded as having applied to make one yet, and a single company usually brings only a modest drop. See the price pattern
What should I do now?
Keep taking Aphexda as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Aphexda by the Numbers
- Reason
- FDA exclusivity endsFDA gives new drugs a protected period, for example for a rare-disease use. It ends then.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- None filed yet No filers on record
- Brand sales
- $9M a yearSmaller seller
- FDA approved 2023 September 2023 FDA Orange Book
- Patents listed 2 last runs to December 2041 A generic is expected sooner, in September 2030. See why FDA Orange Book
Aphexda’s Road to a Generic
Aphexda has had the market to itself since the FDA approved it in September 2023 (Ayrmid Pharma Ltd). Its FDA protection (orphan drug) runs to September 2030. Its 2 listed patents run to December 2041.
The first generic of Aphexda is expected in September 2030.
Why that month: FDA gives new drugs a protected period, for example for a rare-disease use. It ends then. That is about 11.5 years before the last listed patent runs out, in December 2041.
Why a Generic Can Come Before December 2041
The last listed patent runs to December 2041, but it covers the product’s formulation, not the medicine itself, which a generic can often work around or challenge. Dr. Brian explains
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Aphexda Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Aphexda’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 12,257,285 | The product’s formulation | December 2041 | Active |
| 12,268,725 | The product’s formulation | December 2041 | Active |
| Exclusivity | What it means | Ends | Status |
|---|---|---|---|
| New chemical entity NCE | Five years of protection for a medicine whose active ingredient the FDA had never approved before. | September 2028 | Active |
| Orphan drug ODE-442 | Seven years of protection for a use in a rare disease. | September 2030 | Active |
Source: FDA Orange Book, application 217159. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Motixafortide Acetate
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No company is recorded as having applied to the FDA to make a generic Aphexda yet.
Approved by the FDA
Not yet. The FDA has not approved a generic motixafortide acetate. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic motixafortide acetate for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Aphexda Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Aphexda, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
Aphexda Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| EQ 62MG BASE/VIAL | Powder | Subcutaneous | September 2023 | Prescription reference product |
Source: FDA Orange Book, Ayrmid Pharma Ltd. Listed for sale today by BioLineRx USA Inc and Gamida Cell Inc. (FDA NDC Directory).
Aphexda NDC Codes and Packages
Each Aphexda package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 73441-0062-01 | MOTIXAFORTIDE ACETATE 62 mg/1.7mL injection, powder, lyophilized, for solution | vial of 1.7 mL | Gamida Cell Inc. |
| 82737-0073-01 | MOTIXAFORTIDE ACETATE 62 mg/1.7mL injection, powder, lyophilized, for solution | vial of 1.7 mL | BioLineRx USA Inc |
| 82737-0073-01 | MOTIXAFORTIDE ACETATE 62 mg/1.7mL injection, powder, lyophilized, for solution | vial of 1.7 mL | BioLineRx USA Inc |
Source: the FDA NDC Directory, current listings only. Only packages sold under Aphexda’s own FDA approval (NDA 217159) are listed, never a generic. Some codes belong to companies that repackage Aphexda: it is the same medicine in a different package.
What a Generic Aphexda Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Aphexda as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Aphexda”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Aphexda
Is there a generic for Aphexda right now?
No. As of October 9, 2026 no generic motixafortide acetate is listed for sale in the FDA NDC Directory.
When will Aphexda go generic?
September 2030 is the expected month, and that is probable but not certain. It is when Aphexda’s FDA protection for orphan drug ends. Seven years of protection for a use in a rare disease. The last listed patent runs to December 2041, but it covers the product’s formulation, not the medicine itself, which a generic can often work around or challenge.
Will generic motixafortide acetate be the same as Aphexda?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. No company is recorded as having applied to the FDA to make one yet, and a single company usually brings only a modest drop.
Has the FDA approved a generic Aphexda?
Not yet. The FDA Orange Book lists no approved generic version of Aphexda.
When does the Aphexda patent expire?
The FDA Orange Book lists 2 patents for Aphexda; the last runs to December 2041. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (September 2030) weighs all of that.
Changes to This Projection
- First generic expected September 2030 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- GenvoyaCobicistat, Elvitegravir, Emtricitabine, and Tenofovir Alafenamide FumarateDuring 2032
- ZemdriPlazomicin SulfateJune 2032
- LybalviOlanzapine and Samidorphan L-malateMay 2033
- TrikaftaElexacaftor, Ivacaftor, and TezacaftorDecember 2037
- QalsodyTofersen2038 to 2039
- CaldolorIbuprofenTBD no date yet
About Aphexda
- Generic name motixafortide acetate
- How it is taken Injection under the skin
- Company Ayrmid Pharma Ltd
- Hard to copy Inhalers, injectables, patches and other hard-to-copy products. Fewer companies attempt them and dates slip more often.
- More drugs Brand-name drugs starting with A
- Have a question? A pharmacist answers, free. Ask about Aphexda
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.